{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:27:06Z","timestamp":1792193226044,"version":"4.4.0"},"reference-count":54,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,11,1]]},"abstract":"<jats:p>Background. Most girls with Turner syndrome (TS) receive growth hormone (GH) treatment during childhood and adolescence, but controlled data on the effects on body composition and glucose metabolism are lacking.<\/jats:p>\n               <jats:p>Objective. To study the effects of GH treatment on insulin sensitivity, glucose metabolism, bone turnover, and body composition.<\/jats:p>\n               <jats:p>Methods. A randomized, placebo-controlled, crossover study was conducted with girls with TS. All girls with TS were treated with GH 0.1 IU\/kg\/d subcutaneously at bedtime or with placebo for 2 months and studied at the end of each period. Control subjects were studied once without treatment. Twelve girls with TS, aged 9.5 to 14.8 years (median: 12.9 years) and 16 age-matched control subjects (10.3\u201316.0 years; median: 12.1 years) were studied. Twenty-four-hour sampling of blood was performed; GH, insulin-like growth factor I (IGF-I), IGF binding proteins (IGFBPs), insulin, glucose, and lipolytic and gluconeogenic precursors were assayed, followed by an oral glucose tolerance test. Body composition was evaluated by dual-energy x-ray absorptiometry scanning and body mass index (BMI). Fasting bone markers were measured.<\/jats:p>\n               <jats:p>Results. Height was reduced in TS as compared with control subjects. In the placebo situation, 24-hour integrated GH as well as IGF-I was significantly reduced in girls with TS compared with control subjects. Controlling for differences in lean body mass (LBM; or fat mass [FM]) and sexual development did not explain the difference in 24-hour integrated GH. Differences in sexual development, BMI, FM, insulin sensitivity, and IGFBP-3 could explain the difference in IGF-I between TS and control subjects. Carbohydrate metabolism in TS was comparable with control subjects. GH treatment induced insulin resistance, with increments in fasting glucose andinsulin, as well as 24-hour insulin. Circulating levels of lipid and gluconeogenic substrates were comparable in TS and control subjects and unchanged in response to treatment. Bone markers increased in response to GH. Total FM was increased in girls with TS, accounted for by an increased FM in the arms and trunk, whereas LBM was decreased. Especially LBM in the legs was decreased. Overall, bone mineral content was diminished. Treatment with GH reduced FM in TS, especially in the arms and legs, and likewise increased total LBM, primarily in the trunk.<\/jats:p>\n               <jats:p>Conclusion. This study documented evidence of impaired GH secretion and action, disproportionate body composition, but a normal carbohydrate metabolism in girls with TS. Short-term GH administration was associated with favorable changes in body composition but also with relative impairment of glucose tolerance and insulin sensitivity. We recommend that glucose metabolism be monitored carefully during long-term GH treatment in these patients.<\/jats:p>","DOI":"10.1542\/peds.110.5.889","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:17:55Z","timestamp":1092442675000},"page":"889-896","source":"Crossref","is-referenced-by-count":46,"title":["Short-Term Growth Hormone Treatment in Girls With Turner Syndrome Decreases Fat Mass and Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study"],"prefix":"10.1542","volume":"110","author":[{"given":"Claus H\u00f8jbjerg","family":"Gravholt","sequence":"first","affiliation":[{"name":"Medical Department M (Endocrinology and Diabetes) and Medical Research Laboratories, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune Weis","family":"Naeraa","sequence":"additional","affiliation":[{"name":"Medical Department M (Endocrinology and Diabetes) and Medical Research Laboratories, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Pediatric Department, Skejby Sygehus, A\u030arhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Brixen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology C, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark"},{"name":"Department of Endocrinology M, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knud William","family":"Kastrup","sequence":"additional","affiliation":[{"name":"Pediatric Department, Copenhagen County Hospital, Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Mosekilde","sequence":"additional","affiliation":[{"name":"Department of Endocrinology C, Aarhus Amtssygehus, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Otto Lunde","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Medical Department M (Endocrinology and Diabetes) and Medical Research Laboratories, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Sandahl","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Medical Department M (Endocrinology and Diabetes) and Medical Research Laboratories, Aarhus Kommunehospital, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2002,11,1]]},"reference":[{"key":"2021121006370409000_R1","doi-asserted-by":"crossref","unstructured":"Rosenfeld RG, Attie KM, Frane J, et al. Growth hormone therapy of Turner\u2019s syndrome: beneficial effect on adult height. J Pediatr.1998;132:319\u2013324","DOI":"10.1016\/S0022-3476(98)70452-4"},{"key":"2021121006370409000_R2","doi-asserted-by":"crossref","unstructured":"Sas TC, Muinck Keizer-Schrama SM, Stijnen T, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab.1999;84:4607\u20134612","DOI":"10.1210\/jc.84.12.4607"},{"key":"2021121006370409000_R3","doi-asserted-by":"crossref","unstructured":"Jensen MB, Hermann AP, Hessov IB, Mosekilde L. Components of variance when assessing the reproducibility of body composition measurements using bio-impedance and the Hologic QDR-2000 DXA scanner. Clin Nutr.1997;16:61\u201365","DOI":"10.1016\/S0261-5614(97)80024-6"},{"key":"2021121006370409000_R4","doi-asserted-by":"crossref","unstructured":"Abrahamsen B, Gram J, Hansen TB, Beck NH. Cross calibration of QDR-2000 and QDR-1000 dual-energy X-ray densitometers for bone mineral and soft-tissue measurements. Bone.1995;16:385\u2013390","DOI":"10.1016\/8756-3282(94)00054-9"},{"key":"2021121006370409000_R5","doi-asserted-by":"crossref","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia.1985;28:412\u2013419","DOI":"10.1007\/BF00280883"},{"key":"2021121006370409000_R6","doi-asserted-by":"crossref","unstructured":"Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care.1999;22:1462\u20131470","DOI":"10.2337\/diacare.22.9.1462"},{"key":"2021121006370409000_R7","unstructured":"Frystyk J, Dinesen B, Orskov H. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul.1995;5:169\u2013176"},{"key":"2021121006370409000_R8","doi-asserted-by":"crossref","unstructured":"Orskov H, Thomsen HG, Yde H. Wick chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature.1968;219:193\u2013195","DOI":"10.1038\/219193b0"},{"key":"2021121006370409000_R9","doi-asserted-by":"crossref","unstructured":"Lloyd B, Burrin J, Smythe P, Alberti KG. Enzymic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glycerol, and 3-hydroxybutyrate. Clin Chem.1978;24:1724\u20131729","DOI":"10.1093\/clinchem\/24.10.1724"},{"key":"2021121006370409000_R10","doi-asserted-by":"crossref","unstructured":"Price PA, Nishimoto SK. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci U S A.1980;77:2234\u20132238","DOI":"10.1073\/pnas.77.4.2234"},{"key":"2021121006370409000_R11","doi-asserted-by":"crossref","unstructured":"Recommended methods for the determination of four enzymes in blood. Scand J Clin Lab Invest.1974;33:291\u2013306","DOI":"10.3109\/00365517409082499"},{"key":"2021121006370409000_R12","doi-asserted-by":"crossref","unstructured":"Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem.1993;39:635\u2013640","DOI":"10.1093\/clinchem\/39.4.635"},{"key":"2021121006370409000_R13","doi-asserted-by":"crossref","unstructured":"Ranke MB, Blum WF, Haug F, et al. Growth hormone, somatomedin levels and growth regulation in Turner\u2019s syndrome. Acta Endocrinol.1987;116:305\u2013313","DOI":"10.1530\/acta.0.1160305"},{"key":"2021121006370409000_R14","doi-asserted-by":"crossref","unstructured":"Saenger P, Schwartz E, Wiedemann E, Levine LS, Tsai M, New MI. The interaction of growth hormone, somatomedin and oestrogen in patients with Turner\u2019s syndrome. Acta Endocrinol.1976;81:9\u201318","DOI":"10.1530\/acta.0.0810009"},{"key":"2021121006370409000_R15","doi-asserted-by":"crossref","unstructured":"Wit JM, Massarano AA, Kamp GA, et al. Growth hormone secretion in patients with Turner\u2019s syndrome as determined by time series analysis. Acta Endocrinol.1992;127:7\u201312","DOI":"10.1530\/acta.0.1270007"},{"key":"2021121006370409000_R16","doi-asserted-by":"crossref","unstructured":"Massarano AA, Brook CG, Hindmarsh PC, et al. Growth hormone secretion in Turner\u2019s syndrome and influence of oxandrolone and ethinyl oestradiol. Arch Dis Child.1989;64:587\u2013592","DOI":"10.1136\/adc.64.4.587"},{"key":"2021121006370409000_R17","doi-asserted-by":"crossref","unstructured":"Reiter JC, Craen M, Van Vliet G. Decreased growth hormone response to growth hormone-releasing hormone in Turner\u2019s syndrome: relation to body weight and adiposity. Acta Endocrinol.1991;125:38\u201342","DOI":"10.1530\/acta.0.1250038"},{"key":"2021121006370409000_R18","doi-asserted-by":"crossref","unstructured":"Foster CM, Borondy M, Markovs ME, Hopwood NJ, Kletter GB, Beitins IZ. Growth hormone bioactivity in girls with Turner\u2019s syndrome: correlation with insulin-like growth factor I. Pediatr Res.1994;35:218\u2013222","DOI":"10.1203\/00006450-199402000-00019"},{"key":"2021121006370409000_R19","doi-asserted-by":"crossref","unstructured":"Blethen SL, Albertsson Wikland K, Faklis EJ, Chasalow FI. Circulating growth hormone isoforms in girls with Turner\u2019s syndrome. J Clin Endocrinol Metab.1994;78:1439\u20131443","DOI":"10.1210\/jcem.78.6.8200948"},{"key":"2021121006370409000_R20","doi-asserted-by":"crossref","unstructured":"Ishikawa M, Yokoya S, Tachibana K, et al. Serum levels of 20-kilodalton human growth hormone (GH) are parallel those of 22-kilodalton human GH in normal and short children. J Clin Endocrinol Metab.1999;84:98\u2013104","DOI":"10.1210\/jcem.84.1.5402"},{"key":"2021121006370409000_R21","doi-asserted-by":"crossref","unstructured":"Ross JL, Long LM, Loriaux DL, Cutler GBJ. Growth hormone secretory dynamics in Turner syndrome. J Pediatr.1985;106:202\u2013206","DOI":"10.1016\/S0022-3476(85)80287-0"},{"key":"2021121006370409000_R22","doi-asserted-by":"crossref","unstructured":"Zadik Z, Landau H, Chen M, Altman Y, Lieberman E. Assessment of growth hormone (GH) axis in Turner\u2019s syndrome using 24-hour integrated concentrations of GH, insulin-like growth factor-I, plasma GH-binding activity, GH binding to IM9 cells, and GH response to pharmacological stimulation. J Clin Endocrinol Metab.1992;75:412\u2013416","DOI":"10.1210\/jcem.75.2.1386373"},{"key":"2021121006370409000_R23","doi-asserted-by":"crossref","unstructured":"Gravholt CH, Frystyk J, Flyvbjerg A, Orskov H, Christiansen JS. Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids. Am J Physiol.280:E308\u2013E314,2001","DOI":"10.1152\/ajpendo.2001.280.2.E308"},{"key":"2021121006370409000_R24","doi-asserted-by":"crossref","unstructured":"Gravholt CH, Veldhuis JD, Christiansen JS. Increased disorderliness and decreased mass and daily rate of endogenous growth hormone secretion in adult Turner syndrome: the impact of body composition, maximal oxygen uptake and treatment with sex hormones. Growth Horm IGF Res.1998;8:289\u2013298","DOI":"10.1016\/S1096-6374(98)80124-X"},{"key":"2021121006370409000_R25","doi-asserted-by":"crossref","unstructured":"Gravholt CH, Naeraa RW, Fisker S, Christiansen JS. Body composition and physical fitness are major determinants of the growth hormone-IGF axis aberrations in adult Turner syndrome, with important modulations by treatment with 17-beta-estradiol. J Clin Endocrinol Metab.1997;82:2570\u20132577","DOI":"10.1210\/jc.82.8.2570"},{"key":"2021121006370409000_R26","doi-asserted-by":"crossref","unstructured":"Juul A, Bang P, Hertel NT, et al. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab.1994;78:744\u2013752","DOI":"10.1210\/jc.78.3.744"},{"key":"2021121006370409000_R27","doi-asserted-by":"crossref","unstructured":"Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L, Christiansen JS. Marked disproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome. A cross-sectional study. J Clin Endocrinol Metab.2002;87:2798\u20132808","DOI":"10.1210\/jcem.87.6.8598"},{"key":"2021121006370409000_R28","doi-asserted-by":"crossref","unstructured":"Vestergaard P, Hermann AP, Orskov H, Mosekilde L. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study. J Clin Endocrinol Metab.1999;84:2286\u20132290","DOI":"10.1210\/jc.84.7.2286"},{"key":"2021121006370409000_R29","doi-asserted-by":"crossref","unstructured":"Neely EK, Marcus R, Rosenfeld RG, Bachrach LK. Turner syndrome adolescents receiving growth hormone are not osteopenic. J Clin Endocrinol Metab.1993;76:861\u2013866","DOI":"10.1210\/jcem.76.4.8473397"},{"key":"2021121006370409000_R30","doi-asserted-by":"crossref","unstructured":"Lanes R, Gunczler P, Paoli M, Weisinger JR. Bone mineral density of prepubertal age girls with Turner\u2019s syndrome while on growth hormone therapy. Horm Res.1995;44:168\u2013171","DOI":"10.1159\/000184619"},{"key":"2021121006370409000_R31","doi-asserted-by":"crossref","unstructured":"Bertelloni S, Cinquanta L, Baroncelli GI, Simi P, Rossi S, Saggese G. Volumetric bone mineral density in young women with Turner\u2019s syndrome treated with estrogens or estrogens plus growth hormone. Horm Res.2000;53:72\u201376","DOI":"10.1159\/000023517"},{"key":"2021121006370409000_R32","doi-asserted-by":"crossref","unstructured":"Sas TC, Muinck Keizer-Schrama SM, Stijnen T, et al. A longitudinal study on bone mineral density until adulthood in girls with Turner\u2019s syndrome participating in a growth hormone injection frequency-response trial. Clin Endocrinol (Oxf).2000;52:531\u2013536","DOI":"10.1046\/j.1365-2265.2000.00963.x"},{"key":"2021121006370409000_R33","doi-asserted-by":"crossref","unstructured":"Brixen K, Nielsen HK, Mosekilde L, Flyvbjerg A. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res.1990;5:609\u2013618","DOI":"10.1002\/jbmr.5650050610"},{"key":"2021121006370409000_R34","doi-asserted-by":"crossref","unstructured":"Marcus R, Butterfield G, Holloway L, et al. Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab.1990;70:519\u2013527","DOI":"10.1210\/jcem-70-2-519"},{"key":"2021121006370409000_R35","doi-asserted-by":"crossref","unstructured":"Brixen K, Kassem M, Nielsen HK, Loft AG, Flyvbjerg A, Mosekilde L. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study. J Bone Miner Res.1995;10:1865\u20131874","DOI":"10.1002\/jbmr.5650101205"},{"key":"2021121006370409000_R36","doi-asserted-by":"crossref","unstructured":"Hansen TB, Brixen K, Vahl N, et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab.1996;81:3352\u20133359","DOI":"10.1210\/jc.81.9.3352"},{"key":"2021121006370409000_R37","doi-asserted-by":"crossref","unstructured":"Brixen K, Hansen TB, Hauge E, et al. Growth hormone treatment in adults with adult-onset growth hormone deficiency increases iliac crest trabecular bone turnover: a 1-year, double-blind, randomized, placebo-controlled study. J Bone Miner Res.2000;15:293\u2013300","DOI":"10.1359\/jbmr.2000.15.2.293"},{"key":"2021121006370409000_R38","doi-asserted-by":"crossref","unstructured":"Ikkos D, Luft R, Gemzell CA. The effect of human growth hormone in man. Lancet.1958;1:720\u2013721","DOI":"10.1016\/S0140-6736(58)91141-3"},{"key":"2021121006370409000_R39","doi-asserted-by":"crossref","unstructured":"Raben MS, Hollenberg CH. Effect of growth hormone on plasma fatty acids. J Clin Invest.1959;38:484\u2013488","DOI":"10.1172\/JCI103824"},{"key":"2021121006370409000_R40","doi-asserted-by":"crossref","unstructured":"Caprio S, Boulware S, Diamond M, et al. Insulin resistance: an early metabolic defect of Turner\u2019s syndrome. J Clin Endocrinol Metab.1991;72:832\u2013836","DOI":"10.1210\/jcem-72-4-832"},{"key":"2021121006370409000_R41","unstructured":"Stoppoloni G, Prisco F, Alfano C, Iafusco D, Marrazzo G, Paolisso G. Characteristics of insulin resistance in Turner syndrome. Diabetes Metab.1990;16:267\u2013271"},{"key":"2021121006370409000_R42","doi-asserted-by":"crossref","unstructured":"Gravholt CH, Nyholm B, Saltin B, Schmitz O, Christiansen JS. Muscle fiber composition and capillary density in Turner syndrome: evidence of increased muscle fiber size related to insulin resistance. Diabetes Care.2001;24:1668\u20131673","DOI":"10.2337\/diacare.24.9.1668"},{"key":"2021121006370409000_R43","doi-asserted-by":"crossref","unstructured":"Larsson H, Daugaard JR, Kiens B, Richter EA, Ahren B. Muscle fiber characteristics in postmenopausal women with normal or impaired glucose tolerance. Diabetes Care.1999;22:1330\u20131338","DOI":"10.2337\/diacare.22.8.1330"},{"key":"2021121006370409000_R44","doi-asserted-by":"crossref","unstructured":"Heinze E, Schlickenrieder J, Holl RW, Ebert R. Reduced secretion of gastric inhibitory polypeptide in Turner patients with impaired glucose tolerance. Eur J Pediatr.1991;150:339\u2013342","DOI":"10.1007\/BF01955936"},{"key":"2021121006370409000_R45","unstructured":"Heinze E, Clark PMS, Hales CN, Orskov C, Ebert W, Holl RW. Reduced GIP contributes to altered insulin response following oral glucose in women with Turner syndrome. Diabetologia.1993;36(suppl 1):A48\u2013A48. Abstract 182"},{"key":"2021121006370409000_R46","doi-asserted-by":"crossref","unstructured":"Wilson DM, Frane JW, Sherman B, Johanson AJ, Hintz RL, Rosenfeld RG. Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone, and a combination of both. J Pediatr.1988;112:210\u2013217","DOI":"10.1016\/S0022-3476(88)80057-X"},{"key":"2021121006370409000_R47","doi-asserted-by":"crossref","unstructured":"Caprio S, Boulware SD, Press M, et al. Effect of growth hormone treatment on hyperinsulinemia associated with Turner syndrome. J Pediatr.1992;120:238\u2013243","DOI":"10.1016\/S0022-3476(05)80434-2"},{"key":"2021121006370409000_R48","doi-asserted-by":"crossref","unstructured":"Sas TC, Muinck Keizer-Schrama SM, Stijnen T, Aanstoot HJ, Drop SL. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. J Clin Endocrinol Metab.2000;85:769\u2013775","DOI":"10.1210\/jc.85.2.769"},{"key":"2021121006370409000_R49","doi-asserted-by":"crossref","unstructured":"Ranke MB, Pfluger H, Rosendahl W, et al. Turner syndrome: spontaneous growth in 150 cases and review of the literature. Eur J Pediatr.1983;141:81\u201388","DOI":"10.1007\/BF00496795"},{"key":"2021121006370409000_R50","doi-asserted-by":"crossref","unstructured":"Phipps K, Barker DJ, Hales CN, Fall CH, Osmond C, Clark PM. Fetal growth and impaired glucose tolerance in men and women. Diabetologia.1993;36:225\u2013228","DOI":"10.1007\/BF00399954"},{"key":"2021121006370409000_R51","doi-asserted-by":"crossref","unstructured":"Ibanez L, Dimartino-Nardi J, Potau N, Saenger P. Premature adrenarche\u2014normal variant or forerunner of adult disease?Endocr Rev.2000;21:671\u2013696","DOI":"10.1210\/edrv.21.6.0416"},{"key":"2021121006370409000_R52","doi-asserted-by":"crossref","unstructured":"Larizza D, Cuccia M, Martinetti M, et al. Adrenocorticotrophin stimulation and HLA polymorphisms suggest a high frequency of heterozygosity for steroid 21-hydroxylase deficiency in patients with Turner\u2019s syndrome and their families. Clin Endocrinol (Oxf).1994;40:39\u201345","DOI":"10.1111\/j.1365-2265.1994.tb02441.x"},{"key":"2021121006370409000_R53","doi-asserted-by":"crossref","unstructured":"Balducci R, Toscano V, Larizza D, et al. Effects of long-term growth hormone therapy on adrenal steroidogenesis in Turner syndrome. Horm Res.1998;49:210\u2013215","DOI":"10.1159\/000023173"},{"key":"2021121006370409000_R54","doi-asserted-by":"crossref","unstructured":"Gravholt CH, Naeraa RW. Reference values for body proportions and body composition in adult women with Turner\u2019s syndrome. Am J Med Genet.1997;72:403\u2013408","DOI":"10.1002\/(SICI)1096-8628(19971112)72:4<403::AID-AJMG6>3.0.CO;2-R"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/110\/5\/889\/1116629\/pe1102000889.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/110\/5\/889\/1116629\/pe1102000889.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T15:15:31Z","timestamp":1639149331000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/110\/5\/889\/64465\/Short-Term-Growth-Hormone-Treatment-in-Girls-With"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2002,11,1]]},"published-print":{"date-parts":[[2002,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.110.5.889","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11,1]]}}}